Who invested in Atropos Health

One round we have observed, with the 10 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$33Mraised across 1 round since 2024, from 2 sources

Latest round: Series B, $33MMay 2024
Led by: Valtruis
Investors: 10 (1 led)

See who backed them

The rounds

May 2024
Series B$33M
Reported by Firms' own news pages and 1 otherSEC filing: $33M sold, first sale May 2024

Founders and team

From Atropos Health's own website and the SEC filings it signed: 8 on the team.

Cory WiegertChief Operating Officer
Drew TuritzChief Financial Officer
Kevin SmithChief Growth Officer
Sylvia IslerChief Technology Officer
Ls AbBoard
Brigham HydeExecutive Officer, Directori
Mike SpadaforeManaging Director of Valtruis
Saurabh GombarExecutive Officeri

On the board, as filediNigam Shah

AdvisersCecily HarrisDr. Gabriel Eichler

Everyone who backed them

ValtruisVC firm1round, led 1

GaingelsPrivate equity1round

Samsung NextCorporate VC1round

SanofiInvestment firm1round

Breyer CapitalPrivate equity1round

Merck Global Health Innovation FundCorporate VC1round

Presidio VenturesCorporate VC1round

Emerson CollectiveFamily office1round

McKesson VenturesGrowth equity1round

CencoraCorporate VC1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Atropos Health as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.